地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:15172431432
邮箱:sales@amyjet.com

艾美捷科技代理Monosan品牌。
MONOSAN公司,自1979年生产销售第一个抗大鼠T细胞单克隆抗体以来,一直为生命科学研究领域提供抗体和试剂。产品线包含单克隆抗体、多克隆抗体及试剂,产品系列包括:
(1)MONOSAN® Xtra系列
MONOSAN®Xtra常规MONOSAN®产品线的独特补充。MONOSAN® Xtra系列中的抗体特别适用于冷冻和FFPE组织切片的免疫组织化学(IHC)和免疫荧光(IF)研究。MONOSAN® Xtra单
克隆和多克隆抗体被证明具有优良的品质并显示出高一致性。
(2)MONOSAN®即用型系列
为了减少组织病理学工作流程并消除免疫染色中的不确定性,MONOSAN®设计了一种名为MONOSAN®即用型的预稀释抗体系。该系列包含用于冷冻和FFPE组织切片的免疫组织化学(IHC)
抗体产品。
(3)MONOSAN® 试剂系列
除了常规抗体产品外,MONOSAN®还提供MONOSAN®试剂。该产品线包含用于免疫组化目的的大量检测系统组合,如 MONOSAN® Plus(AP)聚合物试剂盒、MONOSAN® Plus (HRP)
广谱试剂盒和MONOSAN®(HRP)广谱试剂盒。MONOSAN®试剂检测试剂盒设计用于定性检测固定石蜡包埋组织切片、冷冻组织切片和细胞学样品中的抗原。
< " data-original="http://synaptic.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Monosan品牌"> 艾美捷科技代理Monosan品牌
Affinity Biosciences成立于2006年,是一家开创性的生命科学和高科技公司,其生化产品和服务主要应用于生物技术,医学研究和药物开发。Affinity Biosciences致力于通过创新推动客户成功,在英国和美国建立了研发部门,旨在为全球提供卓越的服务。我们的客户包括科学家和技术人员在生命科学公司,大学和政府机构,医院和行业。为了强化对客户的承诺,提升服务水平,我们在中华人民共和国开设了包装和质量控制设施。我们的目标是开发重点是细胞信号转导研究的高质量抗体,包括Akt,AMPK,NF-KappaB,TGF-β等,以及抑制剂和相关试剂。
Founded in 2006, Affinity Biosciences is a pioneering Life Science and High-Tech company whose biochemical products and services are mainly applied in biotechnology, medical research and pharmaceutical development.
Dedicating to advancing customer success through innovation, Affinity Biosciences has established R&D affiliates in the United Kingdom and United States with the aim of providing outstanding service around the globe.Our customers include scientists and technologists in life science companies, university and government institutions, hospitals and industry. To underline our commitment to our customers and enhance our standards of service, we have opened packaging and quality control facilities in the People’s Republic of China. Our goal is to develop high-quality antibody that focuses on Cell Signaling Transduction research, including Akt,AMPK,NF-KappaB,TGF-beta,etc,as well as inhibitors and related reagents.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://synaptic.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Affinity Biosciences"> Affinity Biosciences
艾美捷科技代理Eagle Biosciences公司产品。
Eagle Biosciences公司是多种ELISA试剂盒的领先供应商,产品包括:高效液相色谱法测定试剂盒、ELISA检测试剂盒,抗体和蛋白质。
Eagle Biosciences has quickly become a leading provider of immunoassays, antibodies, and proteins to the worldwide research and clinical communities. Our staff has over 25 years in both the research and diagnostics industries with over 10 years in commercialization and distribution. We offer EagleBio developed products in addition to distributing products from over twenty European organizations. With all of these offerings, we keep our primary focus on providing esoteric and innovative products that aid medical research and clinical laboratories.
Eagle Biosciences公司的主要产品包括:
Bone Metabolism Kits
Cancer Biomarker Kits
Cardiovascular Assay Kits
Drug Monitoring Assay Kits
Endocrine Assay Kits
GastroIntestinal Assays
Immunology Assay Kits
Neurobiology Assay Kits
Antibodies
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Neuromab是一家由NIH资助成立的单克隆抗体库。
The UC Davis/NIH NeuroMab Facility is a national monoclonal antibody-generating resource funded by the National Institutes of Health (NIH). The mission of the UC Davis/NIH NeuroMab Facility is to provide a unique neuroscience-based approach to generating mouse monoclonal antibodies optimized for use in mammalian brain (NeuroMabs). NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the UC Davis/NIH NeuroMab Facility screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e., NeuroMabs): for immunohistochemical- based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks.
Neuromab的主要产品包括:
Array Tomography
Model Organisms
Disease Targets
产品列表:
| 抗体名称 |
| Anti-5-formylcytidine, NeuroMab clone N358/68 |
| Anti-5-hydroxymethylcytidine, NeuroMab clone N297/59 |
| Anti-6xHis, NeuroMab clone N144/14 |
| Anti-ADAM11, NeuroMab clone N441/35 |
| Anti-ADAM22-cytoplasmic, NeuroMab clone N46/30 |
| Anti-ADAM22-extracellular, NeuroMab clone N57/2 |
| Anti-AGPS neo-epitope, NeuroMab clone N444/63 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/39 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/31 |
| Anti-Alg13, NeuroMab clone N442/28 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/80 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/51 |
| Anti-AMIGO-1, NeuroMab clone L86/33 |
| Anti-AMIGO-1, NeuroMab clone L86/36 |
| Anti-AMIGO-1, NeuroMab clone L86A/37 |
| Anti-Ankyrin-B, NeuroMab clone N105/13 |
| Anti-Ankyrin-B, NeuroMab clone N105/17 |
| Anti-Ankyrin-G, NeuroMab clone N106/20 |
| Anti-Ankyrin-G, NeuroMab clone N106/36 |
| Anti-Ankyrin-G, NeuroMab clone N106/65 |
| Anti-Ankyrin-G, NeuroMab clone N106/43 |
| Anti-Ankyrin-R, NeuroMab clone N388A/10 |
| Anti-Ankyrin-R/G, NeuroMab clone N388A/27 |
| Anti-ANO3/TMEM16C, NeuroMab clone N454/91 |
| Anti-ANO5/TMEM16E, NeuroMab clone N421A/85 |
| Anti-ANO6/TMEM16F, NeuroMab clone N429/19 |
| Anti-ARHGAP4, NeuroMab clone N290B/25 |
| Anti-Arl13b, NeuroMab clone N295B/66 |
| Anti-Arx, NeuroMab clone N411/51 |
| Anti-ASIC1, NeuroMab clone N271/44 |
| Anti-ATAT1, NeuroMab clone N347/42 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/8 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/3 |
| Anti-Ataxin-1 wild-type, NeuroMab clone N65/37 |
| Anti-ATF4, NeuroMab clone N360A/24 |
| Anti-BAF53a, NeuroMab clone N336B/83 |
| Anti-BAF53b, NeuroMab clone N332B/15 |
| Anti-Bassoon, NeuroMab clone L124/59 |
| Anti-BBS3/Arl6, NeuroMab clone N302/10 |
| Anti-BBS5, NeuroMab clone N304B/115 |
| Anti-BDNF, NeuroMab clone N450/53 |
| Anti-Beta1-spectrin, NeuroMab clone N385/21 |
| Anti-Beta4-spectrin, NeuroMab clone N393/2 |
| Anti-Beta4-spectrin, NeuroMab clone N393/76 |
| Anti-BKBeta2 potassium channel subunit, NeuroMab clone N53/32 |
| Anti-BKBeta3a potassium channel subunit, NeuroMab clone N40B/18 |
| Anti-BKBeta4 potassium channel, NeuroMab clone L18A/3 |
| Anti-Botch1/Chac1, NeuroMab clone N116/14 |
| Anti-Bral1, NeuroMab clone N364/10 |
| Anti-Bral1, NeuroMab clone N364/42 |
| Anti-Brevican, NeuroMab clone N294A/6 |
| Anti-Brevican, NeuroMab clone N294A/10 |
| Anti-CALB1/calbindin, NeuroMab clone L109/39 |
| Anti-CALB1/calbindin, NeuroMab clone L109/57 |
| Anti-CALB2/calretinin, NeuroMab clone L122/6 |
| Anti-CALB2/calretinin, NeuroMab clone L122/68 |
| Anti-CASK scaffolding protein, NeuroMab clone K56A/50 |
| Anti-Caspr/paranodin/neurexin IV, NeuroMab clone K65/35 |
| Anti-Caspr2/paranodin, NeuroMab clone K67/25 |
| Anti-Cav1.2 calcium channel, NeuroMab clone L57/46 |
| Anti-Cav1.2, NeuroMab clone N263/31 |
| Anti-Cav1.3 calcium channel, NeuroMab clone L48A/9 |
| Anti-Cav1.3 calcium channel, NeuroMab clone N38/8 |
| Anti-Cav3.1 Ca2+ channel, NeuroMab clone N178A/9 |
| Anti-Cav3.2 calcium channel, NeuroMab clone N55/10 |
| Anti-Cav1 calcium channel, NeuroMab clone N7/18 |
| Anti-Cav尾2 calcium channel subunit, NeuroMab clone N8b/1 |
| Anti-Cav3 calcium channel, NeuroMab clone N473/36 |
| Anti-Cav尾4 calcium channel, NeuroMab clone N10/7 |
| Anti-Cdkl5, NeuroMab clone EA7 |
| Anti-CDY1/2, NeuroMab clone N143/38 |
| Anti-CDY1/2/L1/L2, NeuroMab clone N143/36 |
| Anti-Celf4/Brunol4, NeuroMab clone N446/80 |
| Anti-FOS, NeuroMab clone N486/32 |
| Anti-FOS, NeuroMab clone N486/76 |
| Anti-Clcn3, NeuroMab clone N258/5 |
| Anti-Clcn4, NeuroMab clone N222/6 |
| Anti-Clcn5, NeuroMab clone N406/47 |
| Anti-CLN3, NeuroMab clone N380/87 |
| Anti-CLN6, NeuroMab clone N400/24 |
| Anti-CNGA1/3 cyclic nucleotide-gated channel, NeuroMab clone L36/12 |
| Anti-Collybistin, NeuroMab clone L120/12 |
| Anti-Collybistin, NeuroMab clone L120/30 |
| Anti-Contactin/F3 scaffold protein, NeuroMab clone K73/20 |
| Anti-Copper-transporting ATPase 1, NeuroMab clone L60/4 |
| Anti-Copper-transporting ATPase 2 (Copper pump 2, Wilsons disease-associated protein, NeuroMab clone L62/29 |
| Anti-Co-Rest/RCOR1 Transcriptional Co-Repressor, NeuroMab clone K72/8 |
| Anti-DEPDC5, NeuroMab clone N463/52 |
| Anti-Dicer, NeuroMab clone N167/7 |
| Anti-DLX1 transcription factor, NeuroMab clone L43/40 |
| Anti-DNAH1, NeuroMab clone N251/14 |
| Anti-DNAH7, NeuroMab clone N250/21 |
| Anti-DNAIC1, NeuroMab clone UNC 65.56.18.11 |
| Anti-DNMT3L, NeuroMab clone N117/9 |
| Anti-Doc2b, NeuroMab clone N150/21 |
| Anti-Dopamine D2 receptor, NeuroMab clone N186/29 |
| Anti-Dopamine D3 receptor, NeuroMab clone N331/19 |
| Anti-EAAC1, NeuroMab clone N420/24 |
| Anti-FGF11 (Fibroblast growth factor 11), NeuroMab clone N92/14 |
| Anti-FGF12/FHF1, NeuroMab clone N94/17 |
| Anti-FGF13 (Fibroblast growth factor 13), NeuroMab clone N91/27 |
| Anti-FGF13B/FHF2B, NeuroMab clone N225A/10 |
| Anti-FGF14/FHF4, NeuroMab clone N56/21 |
| Anti-Fig4/Sac3, NeuroMab clone N202/7 |
| Anti-Flrt3, NeuroMab clone N353/13 |
| Anti-Foxi2, NeuroMab clone N349/96 |
| Anti-Foxi3, NeuroMab clone N359/28 |
| Anti-Frataxin, NeuroMab clone N191/7 |
| Anti-GABA-A-R-Alpha1, NeuroMab clone N95/35 |
| Anti-GABA-A-R-Alpha2, NeuroMab clone N399/19 |
| Anti-GABA-A-R-Alpha4, NeuroMab clone N398A/34 |
| Anti-GABA-A-R-Alpha5, NeuroMab clone N415/24 |
| Anti-GABA-A-R-Alpha6, NeuroMab clone N229A/32 |
| Anti-GABA-A-R-Beta1, NeuroMab clone N96/55 |
| Anti-GABA-A-R-Beta2/3, NeuroMab clone 62-3G1 |
| Anti-GABA-A-R-Beta3, NeuroMab clone N87/25 |
| Anti-Delta GABA-A receptor, NeuroMab clone N151/3 |
| Anti-GABA-A-R-Epsilon, NeuroMab clone N413/67 |
| Anti-GABA-A-R-Gamma2L, NeuroMab clone N452/69 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/73 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/30 |
| Anti-GABA-A-R-Pi, NeuroMab clone N431/64 |
| Anti- GABA-A-R-Theta, NeuroMab clone L123/109 |
| Anti-GABABR1 GABA-B receptor, NeuroMab clone N93A/49 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/2 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/37 |
| Anti-GAD65/67, NeuroMab clone L127/12 |
| Anti-GAD67, NeuroMab clone L127/8 |
| Anti-Gamma-protocadherin-A3, NeuroMab clone N144/17 |
| Anti-Gamma-protocadherin-B2, NeuroMab clone N148/30 |
| Anti-Gamma-protocadherin-C3, NeuroMab clone N174B/27 |
| Anti-Gamma-protocadherin-C4, NeuroMab clone N193A/13 |
| Anti-Gephyrin, NeuroMab clone L106/83 |
| Anti-Gephyrin, NeuroMab clone L106/93 |
| Anti-Gephyrin, NeuroMab clone L106/4 |
| Anti-GFAP, NeuroMab clone N206A/8 |
| Anti-GFAP-R416WT, NeuroMab clone N206B/9 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/8 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/38 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/20 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/44 |
| Anti-GIT1 scaffold protein, NeuroMab clone N39B/8 |
| Anti-GIT2 scaffold protein, NeuroMab clone N83/48 |
| Anti-GluA1/GluR1 glutamate receptor, NeuroMab clone N355/1 |
| Anti-GluA2/GluR2 glutamate receptor, NeuroMab clone L21/32 |
| Anti-KA2 kainate receptor, NeuroMab clone N279B/27 |
| Anti-GluN1/NR1 glutamate receptor, NeuroMab clone N308/48 |
| Anti-NR2A glutamate receptor, NeuroMab clone N327A/38 |
| Anti-GluN2A/NR2A glutamate receptor, NeuroMab clone N327/95 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/20 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/36 |
| Anti-GluN2C/NR2C, NeuroMab clone N422/18 |
| Anti- GluN3A/NR3A, NeuroMab clone N416/40 |
| Anti-Glycine receptor Alpha3, NeuroMab clone N424/45 |
| Anti-Glycine receptor Alpha3L, NeuroMab clone N424/48 |
| Anti-GRK6A/B, NeuroMab clone N142/28 |
| Anti-Gs protein alpha subunit, NeuroMab clone N192/12 |
| Anti-GST (Glutathione S-transferase), NeuroMab clone N100/13 |
| Anti-Haspin/GSG2, NeuroMab clone N128A/2 |
| Anti-HCN1 cyclic nucleotide-gated channel, NeuroMab clone N70/28 |
| Anti-HCN2 cyclic nucleotide-gated channel, NeuroMab clone N71/37 |
| Anti-HCN3 cyclic nucleotide-gated channel, NeuroMab clone N141/28 |
| Anti-HCN4 cyclic nucleotide-gated channel, NeuroMab clone N114/10 |
| Anti-Histone H2A.Z/V, NeuroMab clone N310/21 |
| Anti-Histone H2A.Z acetyl-Lys4/7/11, NeuroMab clone N299/39 |
| Anti-Histone H3.3, NeuroMab clone N158/28 |
| Anti-Histone H3 acetyl-Lys56, NeuroMab clone N307/12 |
| Anti-Histone H3-dimethyl-Arg8, NeuroMab clone N293/50 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/19 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/48 |
| Anti-Histone H4-dimethyl-Arg3, NeuroMab clone N309A/21 |
| Anti-Homer1L, NeuroMab clone L113/27 |
| Anti-Homer1L, NeuroMab clone L113/13 |
| Anti-Homer1, NeuroMab clone L113/130 |
| Anti-ICK, NeuroMab clone N451/73 |
| Anti-Iduna/RNF146, NeuroMab clone N201/35 |
| Anti-INPP4b, NeuroMab clone N171/17 |
| Anti IP3 receptor type 1 NeuroMab clone L24/18 |
| Anti-IRSp53/BAIAP2, NeuroMab clone L117/1 |
| Anti-JIP-2/IB-2, NeuroMab clone N135/37 |
| Anti-JMJD2A, NeuroMab clone N154/32 |
| Anti-KCC2 transporter, NeuroMab clone N1/66 |
| Anti-KCC2 transporter, NeuroMab clone N1/12 |
| Anti-KChIP1 potassium channel, NeuroMab clone K55/7 |
| Anti-KChIP2 potassium channel subunit, NeuroMab clone K60/73 |
| Anti-KChIP3 potassium channel, NeuroMab clone K66/38 |
| Anti-KChIP4 K+ channel, NeuroMab clone N423/75 |
| Anti-KCNT1/Slo2.2/Slack K+ channel, NeuroMab clone N3/26 |
| Anti-KCNT2/Slo2.1/Slick sodium- and chloride-activated ATP sensitive potassium channel, NeuroMab clone N11/33 |
| Anti-KCNU1/Slo3 pH-sensitive maxi potassium channel, NeuroMab clone N2/16 |
| Anti-Keyhole limpet hemocyanin, NeuroMab clone N132A/12 |
| Anti-Kir2.1 potassium channel, NeuroMab clone N112B/14 |
| Anti-Kir2.2 potassium channel, NeuroMab clone N124B/38 |
| Anti-Kir2.3 potassium channel, NeuroMab clone N25/35 |
| Anti-Kir2.4 potassium channel, NeuroMab clone N465/11 |
| Anti-Kir3.3 potassium channel, NeuroMab clone N455/15 |
| Anti-Kir6.1 potassium channel, NeuroMab clone N366/60 |
| Anti-Kir6.2 potassium channel, NeuroMab clone N363/71 |
| Anti-Kirrel3 short and long, NeuroMab clone N321C/49 |
| Anti-Kirrel3 short isoform 3, NeuroMab clone N320/48 |
| Anti-Kv1.1 potassium channel subunit, NeuroMab clone K20/78 |
| Anti-Kv1.1 potassium channel (external), NeuroMab clone K36/15 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K14/16 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone L76/36 |
| Anti-Kv1.3 potassium channel, NeuroMab clone L23/27 |
| Anti-Kv1.4 potassium channel subunit, NeuroMab clone K13/31 |
| Anti-Kv1.4 potassium channel (extracellular), NeuroMab clone L71/5 |
| Anti-Kv1.5 potassium channel, NeuroMab clone K7/45 |
| Anti-Kv1.6 potassium channel subunit, NeuroMab clone K19/36 |
| Anti-Kv1.7 potassium channel, NeuroMab clone N471/27 |
| Anti-Kv11.3 potassium channel, NeuroMab clone N447/24 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L83/11 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone K89/34 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L80/21 |
| Anti-Kv2.1 potassium channel (external), NeuroMab clone K39/25 |
| Anti-Kv2.2 potassium channel, NeuroMab clone K37/89 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372C/51 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/60 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/1 |
| Anti-Kv3.1b potassium channel, NeuroMab clone N16b/8 |
| Anti-Kv3.2 potassium channel, NeuroMab clone N410/17 |
| Anti-Kv3.3 potassium channel, NeuroMab clone N375/67 |
| Anti-Kv3.4 potassium channel, NeuroMab clone N72/16 |
| Anti-Kv4.2 potassium channel subunit, NeuroMab clone L28/4 |
| Anti-Kv4.2 potassium channel (external), NeuroMab clone K57/1 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/41 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/30 |
| Anti-Kv6.1 potassium channel, NeuroMab clone N474/27 |
| Anti-Kv6.4 potassium channel, NeuroMab clone N458/10 |
| Anti-KCNQ1 potassium channel, NeuroMab clone N37A/10 |
| Anti-KCNQ2 potassium channel, NeuroMab clone N26A/23 |
| Anti-KCNQ4 potassium channel, NeuroMab clone N43/6 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/88 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/50 |
| Anti-Kv9.1 potassium channel, NeuroMab clone N461/19 |
| Anti-Kv9.2 potassium channel, NeuroMab clone N460/19 |
| Anti-Kvβ1.1 potassium channel subunit, NeuroMab clone K9/40 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K47/42 |
| Anti-Kv尾2 potassium channel, NeuroMab clone K17/70 |
| Anti-Laforin, NeuroMab clone N84/37 |
| Anti-LAR/PTPRF, NeuroMab clone N165/38 |
| Anti-Lgi1, NeuroMab clone N283/7 |
| Anti-Lhx6.1, NeuroMab clone N228A/16 |
| Anti-LRP4 (cytoplasmic), NeuroMab clone N164/6 |
| Anti-LRP4 (extracellular), NeuroMab clone N207/27 |
| Anti-LRRK1, NeuroMab clone N341/37 |
| Anti-LRRK1, NeuroMab clone N341/12 |
| Anti-LRRK2/Dardarin, NeuroMab clone N241A/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone N231B/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone 8G10 |
| Anti-LRRK2/Dardarin, NeuroMab clone N138/6 |
| Anti-LRRK2/Dardarin-pSer910, NeuroMab clone 1D8 |
| Anti-LRRTM2, NeuroMab clone N209C/35 |
| Anti-LRRTM4, NeuroMab clone N205B/22 |
| Anti-Mad3, NeuroMab clone N129A/6 |
| Anti-Mad3, NeuroMab clone N129/15 |
| Anti-Malin, NeuroMab clone N85/18 |
| Anti-MBP (Maltose-binding protein), NeuroMab clone N128A/4 |
| Anti-MAP3K12, NeuroMab clone N377/20 |
| Anti-MAP3K12, NeuroMab clone N377/83 |
| Anti-MECP2, NeuroMab clone N227/21 |
| Anti-MESD, NeuroMab clone N88/12 |
| Anti-MFF, NeuroMab clone N382/14 |
| Anti-MFF (exon 1), NeuroMab clone N382/69 |
| Anti-MGL, NeuroMab clone N90/20 |
| Anti-mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/3 |
| Anti- mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/33 |
| Anti-Miro2, NeuroMab clone N384/63 |
| Anti-MiRP4 potassium channel, NeuroMab clone N472/88 |
| Anti-Mitofusin-1 (Mfn1), NeuroMab clone N111/24 |
| Anti-Mitofusin-2 (Mfn2), NeuroMab clone N153/5 |
| Anti-MMACHC, NeuroMab clone N230/21 |
| Anti-MMP9 metalloproteinase, NeuroMab clone L51/82 |
| Anti-MOG, NeuroMab clone L94/54 |
| Anti-Mortalin/GRP75, NeuroMab clone N52A/42 |
| Anti-MPP8, NeuroMab clone N119/44 |
| Anti-NALCN, NeuroMab clone N185/7 |
| Anti-Nav1.1 sodium channel, NeuroMab clone K74/71 |
| Anti-Nav1.2 sodium channel, NeuroMab clone K69/3 |
| Anti-Nav1.4 sodium channel, NeuroMab clone N255/38 |
| Anti-Nav1.5 sodium channel, NeuroMab clone N397/19 |
| Anti-Nav1.6 sodium channel, NeuroMab clone K87A/10 |
| Anti-Nav1.7 sodium channel, NeuroMab clone N68/6 |
| Anti-Nav1.8 sodium channel, NeuroMab clone N134/12 |
| Anti-Navbeta1 Na+ channel, NeuroMab clone N405/74 |
| Anti-Navbeta2 Na+ channel, NeuroMab clone N395/68 |
| Anti-Navbeta3 Na+ channel, NeuroMab clone N396/29 |
| Anti-Navbeta4 sodium channel, NeuroMab clone N168/6 |
| Anti-NCKX4, NeuroMab clone N414/25 |
| Anti-Neuregulin-CRD (Cysteine-rich domain, Type III), NeuroMab clone N126B/31 |
| Anti-Neuregulin-HBD (Heparin-binding domain, Type I/II), NeuroMab clone N120A/9 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/1 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/26 |
| Anti-Neuroligin-1, NeuroMab clone N97A/31 |
| Anti-Neuroligin-2, NeuroMab clone L107/39 |
| Anti-Neuroligin-3, NeuroMab clone N110/29 |
| Anti-Neuroligin-4*, NeuroMab clone N98/47 |
| Anti-Neuroligin-4*, NeuroMab clone N98/7 |
| Anti-NGL-1 (Netrin-G1 ligand), NeuroMab clone N49A/21 |
| Anti-NGL-2 (Netrin-G2 ligand) NeuroMab clone N50/36 |
| Anti-NGL-3 (Netrin-G3 ligand), NeuroMab clone N51/6 |
| Anti-NKCC1, NeuroMab clone N161/20 |
| Anti-NOS1/nNOS, NeuroMab clone L121/25 |
| Anti-NOS1/nNOS, NeuroMab clone L121/42 |
| Anti-Notch1, NeuroMab clone N253/32 |
| Anti-Npas4, NeuroMab clone N408/62 |
| Anti-Npas4, NeuroMab clone N408/79 |
| Anti-Neuropeptide Y, NeuroMab clone L115/13 |
| Anti-NPY2R, NeuroMab clone L119/106 |
| Anti-NrCAM, NeuroMab clone N343/26 |
| Anti-NSD1, NeuroMab clone N312/10 |
| Anti-NSD3, NeuroMab clone N348/82 |
| Anti-OCRL/INPP5b, NeuroMab clone N166A/26 |
| Anti-Olig1, NeuroMab clone N149/25 |
| Anti-Pan-Ankyrin, NeuroMab clone N388A/60 |
| Anti-Pancortin, NeuroMab clone K96/7 |
| Anti-Pan-FHF-A, NeuroMab clone N235/22 |
| Anti-Pan-Gamma-protocadherin-A, NeuroMab clone N144/32 |
| Anti-Pan-Gamma-protocadherin, NeuroMab clone N159/5 |
| Anti-Pan-GRK, NeuroMab clone N145/20 |
| Anti-Pan-KChIP potassium channel, NeuroMab clone K55/82 |
| Anti-Pan-Kv potassium channel, NeuroMab clone K40/17 |
| Anti-Pan-Kvbeta potassium channel, NeuroMab clone K25/73 |
| Anti-Pan-MAGUK scaffold proteins, NeuroMab clone K28/86 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/40 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/78 |
| Anti-pan-Neurofascin, NeuroMab clone L11A/41 |
| Anti-Pan-Neurofascin (external), NeuroMab clone A12/18 |
| Anti-Pannexin-2, NeuroMab clone N121A/1 |
| Anti-Pannexin-2, NeuroMab clone N121A/31 |
| Anti-Pan-PTPR, NeuroMab clone N165/43 |
| Anti-Pan-QKI, NeuroMab clone N147/6 |
| Anti-Pan-SAPAP, NeuroMab clone N127/31 |
| Anti-pan-Shank (SH3 and multiple ankyrin repeat domains protein) scaffold protein, NeuroMab clone N23B/49 |
| Anti-Pan-Synapsin, NeuroMab clone L125/129 |
| Anti-Pan-Thyroid hormone receptor, NeuroMab clone N403/63 |
| Anti-PARIS/ZNF746, NeuroMab clone N196/16 |
| Anti-Parvalbumin, NeuroMab clone L114/3 |
| Anti-Parvalbumin, NeuroMab clone L114/81 |
| Anti-PEX6, NeuroMab clone N233/8 |
| Anti-PEX7, NeuroMab clone N232/9 |
| Anti-Phosphoserine-2-OEt, NeuroMab clone N257/25 |
| Anti-Phosphoserine-2-OH, NeuroMab clone N259/48 |
| Anti-Phosphoserine-2-OMe, NeuroMab clone N262/16 |
| Anti-PhyH/PAHX, NeuroMab clone N210/5 |
| Anti-PICK1 scaffold, NeuroMab clone L20/8 |
| Anti-PINK1, NeuroMab clone N4/15 |
| Anti-PINK1, NeuroMab clone N4/49 |
| Anti-PINK1, NeuroMab clone N4/19 |
| Anti-PINK1, NeuroMab clone N357/6 |
| Anti-Proser1, NeuroMab clone N456/39 |
| Anti-Prrt2, NeuroMab clone N485/22 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/30 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/28 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/43 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/74 |
| Anti-QKI-5-NLS, NeuroMab clone N195A/16 |
| Anti-QKI-6, NeuroMab clone N182/17 |
| Anti-QKI-7, NeuroMab clone N183/15 |
| Anti-QKI-7b, NeuroMab clone N194/11 |
| Anti-RBM17/SPF45, NeuroMab clone N219/5 |
| Anti-REEP, NeuroMab clone N326D/13 |
| Anti-REEP1, NeuroMab clone N345/51 |
| Anti-REEP1/2, NeuroMab clone N326D/29 |
| Anti-REEP2, NeuroMab clone N326D/2 |
| Anti-Rem2, NeuroMab clone N324/2 |
| Anti-RGS14, NeuroMab clone N133/21 |
| Anti-RGS14, NeuroMab clone N133/35 |
| Anti-Rufy3, NeuroMab clone N483/84 |
| Anti-Rufy3, NeuroMab clone N483/126 |
| Anti-Rufy3, NeuroMab clone N483/26 |
| Anti-S100A5, NeuroMab clone N176A/35 |
| Anti-SALM2 synaptic adhesion-like molecule, NeuroMab clone N52B/27 |
| Anti-SALM5/LRFN5, NeuroMab clone N140A/12 |
| Anti-SAP102 MAGUK scaffold protein, NeuroMab clone N19/2 |
| Anti-SAP97 scaffold protein, NeuroMab clone K64/15 |
| Anti-SAPAP1, NeuroMab clone N238/29 |
| Anti-SAPAP1, NeuroMab clone N238/30 |
| Anti-SAPAP1/2, NeuroMab clone N238/31 |
| Anti-SAPAP2, NeuroMab clone N459/84 |
| Anti-SAPAP3, NeuroMab clone L126/93 |
| Anti-SCG10/stathmin-2, NeuroMab clone L5/1 |
| Anti-SH3GL1, NeuroMab clone K51/1 |
| Anti-Shank1/ SPANK-1/Synamon/SSTRIP scaffold protein, NeuroMab clone N22/21 |
| Anti-Shank1 and Shank3, NeuroMab clone N367/51 |
| Anti-Shank2/ProSAP1/Spank-3/CortBP1 scaffold protein,NeuroMab clone N23B/6 |
| Anti-Shank3 scaffold protein, NeuroMab clone N69/46 |
| Anti-Shank3, NeuroMab clone N367/62 |
| Anti-SK2 potassium channel, NeuroMab clone K78/29 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/23 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/48 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/60 |
| Anti-Snapin (SNAP25 binding protein), NeuroMab clone L8/15 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/37 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/32 |
| Anti-SST/Somatostatin, NeuroMab clone L111/118 |
| Anti-S-tag, NeuroMab clone N56/9 |
| Anti-Stonin-2, NeuroMab clone N346/9 |
| Anti-SUR1, NeuroMab clone N289/16 |
| Anti-SUR1 and SUR2B, NeuroMab clone N323A/31 |
| Anti-SUR2A, NeuroMab clone N319A/14 |
| Anti-SUR2B, NeuroMab clone N323B/20 |
| Anti-SVOP, NeuroMab clone N356/9 |
| Anti-SVOP, NeuroMab clone N356/23 |
| Anti-Synapsin-III, NeuroMab clone L125/121 |
| Anti-Synaptotagmin-10, NeuroMab clone N269/73 |
| Anti-Synaptotagmin-12, NeuroMab clone N277/7 |
| Anti-Synaptotagmin-3, NeuroMab clone N278/19 |
| Anti-Synaptotagmin-5, NeuroMab clone N274/8 |
| Anti-Synaptotagmin-6, NeuroMab clone N270/47 |
| Anti-Synaptotagmin-7, NeuroMab clone N275/14 |
| Anti-Synaptotagmin-9, NeuroMab clone N276A/15 |
| Anti-SynCAM1 cell adhesion molecule, NeuroMab clone L45/30 |
| Anti-SynCAM4, NeuroMab clone N244/5 |
| Anti-SynDIG1/Tmem90b, NeuroMab clone L42/17 |
| Anti-SynDIG3/Tmem91, NeuroMab clone N160/21 |
| Anti-SynDIG4, NeuroMab clone L102/45 |
| Anti-Tafazzin, NeuroMab clone N173B/13 |
| Anti-TALK1 potassium channel, NeuroMab clone N466/14 |
| Anti-TARPGamma2/Stargazin, NeuroMab clone N245/1 |
| Anti-TARPGamma2/4/8, NeuroMab clone N245/36 |
| Anti-TASK1 potassium channel, NeuroMab clone N374/48 |
| Anti-Tauro-GM2, NeuroMab clone N175/9 |
| Anti-THAP1, NeuroMab clone N325B/65 |
| Anti-THIK-2 potassium channel, NeuroMab clone N468/37 |
| Anti-Thioredoxin, NeuroMab clone N245/44 |
| Anti-Thorase (Atad1), NeuroMab clone N125/10 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/13 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/46 |
| Anti- TRAAK potassium channel, NeuroMab clone N445/27 |
| Anti-TRAK1, NeuroMab clone N389/9 |
| Anti-TRAK2, NeuroMab clone N390/43 |
| Anti-TRESK potassium channel, NeuroMab clone N467/1 |
| Anti-TRIP8b (constant), NeuroMab clone N212/7 |
| Anti-TRIP8b (constant), NeuroMab clone N212/17 |
| Anti-TRIP8b (exon 1a/5 junction), NeuroMab clone N291C/22 |
| Anti-TRIP8b (exon 1b), NeuroMab clone N212A/34 |
| Anti-TRIP8b (exon 4), NeuroMab clone N212/3 |
| Anti-TrpC1 calcium channel, NeuroMab clone 1F1 |
| Anti-TrpC4 calcium channel, NeuroMab clone N77/15 |
| Anti-TrpC5 calcium channel, NeuroMab clone N67/15 |
| Anti-TrpC7 calcium channel, NeuroMab clone N64A/36 |
| Anti-TrpM4, NeuroMab clone L88/86 |
| Anti-TrpM6, NeuroMab clone N470/22 |
| Anti-TrpM7 ion channel and Ser/Thr kinase, NeuroMab clone N74/25 |
| Anti-TRPML3/Mucolipin-3, NeuroMab clone N268/19 |
| Anti-TrpV1, NeuroMab clone N221/17 |
| Anti-TrpV1, NeuroMab clone N221/12 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/4 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/39 |
| Anti-TWIK-2 potassium channel, NeuroMab clone N469/28 |
| Anti-Uncx, NeuroMab clone N155/9 |
| Anti-VAChT vesicular acetylcholine transporter, NeuroMab clone N6/38 |
| Anti-VAChT, NeuroMab clone N425/45 |
| Anti-VAPA, NeuroMab clone N479/12 |
| Anti-VAPA, NeuroMab clone N479/22 |
| Anti-VAPA/B, NeuroMab clone N479/107 |
| Anti-VDAC1, NeuroMab clone N152B/23 |
| Anti-Versican, NeuroMab clone N351/23 |
| Anti-Versican, NeuroMab clone N351/24 |
| Anti-VGAT, NeuroMab clone L118/80 |
| Anti-VGAT, NeuroMab clone L118/66 |
| Anti-VGlut1, NeuroMab clone N28/9 |
| Anti-VGlut2, NeuroMab clone N29/29 |
| Anti-VGlut3, NeuroMab clone N34/34 |
| Anti-VIP, NeuroMab clone L108/92 |
| Anti-VMAT1, NeuroMab clone N440/21 |
| Anti-VMAT1, NeuroMab clone N440/61 |
| Anti-Slc18a2/VMAT2, NeuroMab clone N449/73 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/21 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/63 |
| Anti-WAVE1/SCAR, NeuroMab clone K91/36 |
| Anti-WNK1, NeuroMab clone N391/68 |
| Anti-WRN, NeuroMab clone N428/12 |
| Zebrafish PSD Marker, NeuroMab clone N286/74 |
| Anti-Zinedin/Striatin-4, NeuroMab clone K88/64 |
| Anti-ZIP3, NeuroMab clone N476/9 |
| Anti-ZNF423, NeuroMab clone N328B/37 |

艾美捷科技代理Synthego品牌。
Synthego是一家基因组工程公司,致力于加速生命科学研究和开发,以改善人类健康。基于工程和化学基础,Synthego利用自动化和机器学习来合成高质量的CRISPR试剂,用于规模科学。
Synthego的使命是通过为科学家提供每个阶段的全面CRISPR解决方案以及行业领先的全面技术支持,实现从发现到临床的生命科学研究和开发。
Synthego公司的产品包括:
(1)CRISPR核酸酶:hfCas12MaxNuclease,SpCas9核酸酶
(2)阶段特异性SGRNA:合成sgRNA和gRNA、高级RNA、INDeSgRNA、GMPSgRNA
< " data-original="http://synaptic.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Synthego品牌"> 艾美捷科技代理Synthego品牌
<| 产品名称 | 货号 | 化学式 | 分子量 | CAS# |
| 2,5-Anhydro-6-azido-6-deoxy-1,3-O-isopropylidene-D-glucitol | S20031 | C9H15N3O4 | 229,23 | N/A |
| 4-Azido-4-deoxy-1,6:2,3-dianhydro-β-D-mannopyranose | S97085 | C7H9N3O2 | 167,17 | N/A |
| Methyl-3,6-anhydro-7-azido-2,7-dideoxy-4,5-O-isopropylidene-D-alloheptonate | S10191 | C11H17H3O5 | 271,27 | N/A |
| 1,4-Anhydro-3-azido-2-O-benzoyl-3-deoxy-D-xylitol | S10192 | C12H13N3O4 | 263,25 | N/A |
| 1,4-Anhydro-2-azido-3-O-benzoyl-2-deoxy-D-arabitol | S10189 | C12H13N3O4 | 263,25 | N/A |
| 2-Azido-2-deoxy-1,4;3,6-dianhydro-D-glucitol | S03293 | C6H9N3O3 | 171,15 | N/A |
| 6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl-α,β-D-galactopyranose | S05174 | C14H19N3O9 | 373,32 | N/A |
| 6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl-α,β-L-galactopyranose | S02174 | C14H19N3O9 | 373,32 | N/A |
| DIBMA free acid | D-20054 | N/A | N/A | N/A |
| DIBMA monosodium salt | D-20055 | N/A | N/A | N/A |
| Glyco-DIBMA | D-20056 | N/A | N/A | N/A |
| n-Octyl α-D-glucopyranoside (aOG) > 99% highly purified | D97011 | C14H28O6 | 292,38 | 29781-80-4 |
| Methyl 6-O-(-n-heptylcarbamoyl)-α-D-glucopyranoside (HECAMEG) | D20034 | C15H29NO7 | 335,4 | 115457-83-5 |
| n-Hexyl β-D-glucopyranoside > 99% highly purified | D99014 | C12H24O6 | 264,4 | 59080-45-4 |
| n-Heptyl β-D-glucopyranoside (HeptG) > 99% highly purified | D07033 | C13H26O6 | 278,4 | 78617-12-6 |
| n-Octyl β-D-glucopyranoside (OG) > 99% highly purified | D97001 | C14H28O6 | 292,38 | 29836-26-8 |
| n-Octyl β-D-glucopyranoside (OG-C) > 99,5% for crystallography | D97001-C | C14H28O6 | 292,38 | 29836-26-8 |
| n-Nonyl β-D-glucopyranoside (NG) > 99% highly purified | D99011 | C15H30O6 | 306,40 | 69984-73-2 |
| n-Nonyl β-D-glucopyranoside (NG-C) > 99,5% for crystallography | D99011-C | C15H30O6 | 306,40 | 69984-73-2 |
| n-Decyl β-D-glucopyranoside (DG) > 99% highly purified | D99006 | C16H32O6 | 320,43 | 58846-77-8 |
| n-Undecyl β-D-glucopyranoside (UDG) > 99% highly purified | D11023 | C17H34O6 | 334,4 | 70005-86-6 |
| n-Dodecyl β-D-glucopyranoside (DDG) > 99% highly purified | D99007 | C18H36O6 | 348,5 | 59122-55-3 |
| 4-trans-(4-trans-Propylcyclohexyl)-cyclohexyl α-maltoside > 99% (t-PCCαM) | D99019-C | C27H47O11 | 547,67 | N/A |
| n-Dodecyl α-maltoside (αDDM) > 99% highly purified | D99020 | C24H46O11 | 510,63 | 116183-64-3 |
| n-Hexyl β-maltoside (HexM) > 99% highly purified | D20018 | C18H34O11 | 426,4 | 870287-95-9 |
| n-Heptyl β-maltoside (HeptM) > 99% highly purified | D14001 | C19H36O11 | 440,48 | N/A |
| n-Octyl β-maltoside (OM) > 99% highly purified | D20020 | C20H38O11 | 454,4 | 82494-08-4 |
| n-Nonyl β-maltoside (NM) > 99% highly purified | D20015 | C21H40O11 | 468,41 | 106402-05-5 |
| n-Nonyl β-maltoside (NM-C) > 99,5% for crystallography | D20015-C | C21H40O11 | 468,41 | 106402-05-5 |
| n-Decyl β-maltoside (DM) > 99% highly purified | D99003 | C22H42O11 | 482,6 | 82494-09-5 |
| n-Decyl β-maltoside (DM-C) > 99,5% for crystallography | D99003-C | C22H42O11 | 482,6 | 82494-09-5 |
| n-Undecyl β-maltoside (UDM) > 99% highly purified | D99012 | C23H44O11 | 496,6 | 253678-67-0 |
| n-Undecyl β-maltoside (UDM-C) > 99,5% for crystallography | D99012-C | C23H44O11 | 496,6 | 253678-67-0 |
| n-Dodecyl β-maltoside (DDM-C) > 99,5% for crystallography | D97002-C | C24H46O11 | 510,63 | 69227-93-6 |
| n-Tridecyl β-maltoside (TDM) > 99% | D20016 | C25H48O11 | 524,6 | 93911-12-7 |
| n-Tridecyl β-maltoside (TDM-C) > 99,5% for crystallography | D20016-C | C25H48O11 | 524,6 | 93911-12-7 |
| n-Tetradecyl β-maltoside (TeDM-C) > 99,5% for crystallography | D20028-C | C26H50O11 | 538,6 | 18449-82-6 |
| n-Pentadecyl β-maltoside (PDM-C) > 99,5% for crystallography | D20040-C | C27H52O11 | 552,35 | N/A |
| n-Hexadecyl β-maltoside (HeDM) > 99,5% | D20029-C | C28H54O11 | 566,72 | 98064-96-1 |
| n-Dodecyl β-maltoside (DDM) > 99% highly purified | D97002 | C24H46O11 | 510,63 | 69227-93-6 |
| Isopropyl 1-thio-β-D-galactopyranoside (IPTG) | S02122 | C9H18O5 | 238,30 | 367-93-1 |
| n-Heptyl 1-thio-β-D-glucopyranoside (HTG) > 99% highly purified | D99013 | C13H26O5S | 294,4 | 85618-20-8 |
| n-Octyl 1-thio-β-D-glucopyranoside (OTG) > 99% highly purified | D20014 | C14H28O5S | 308,44 | 85618-21-9 |
| n-Nonyl 1-thio-β-D-glucopyranoside (NTG-C) > 99,5% highly purified | D14038-C | C15H30O5S | 322,4 | 98854-15-0 |
| n-Decyl 1-thio-β-D-glucopyranoside (DTG) > 99% highly purified | D20021 | C16H32O5S | 336,4 | 98854-16-1 |
| n-Dodecyl 1-thio-β-maltoside (DDTM-C) > 99,5% highly purified | D20022-C | C24H46O10S | 526,6 | 148565-58-6 |
| n-Heptyl 1-thio-β-D-glucopyranoside (HTG-C) > 99,5% highly purified | D99013-C | C13H26O5S | 294,4 | 85618-20-8 |
| n-Octyl 1-thio-β-D-glucopyranoside (OTG-C) > 99,5% highly purified | D20014-C | C14H28O5S | 308,44 | 85618-21-9 |
| MEGA-8 (N-Octanoyl-N-methylglucamin) | D98004 | C15H31NO6 | 321,4 | 85316-98-9 |
| MEGA-9 (N-Nonanoyl-N-methylglucamin) | D99005 | C16H33NO6 | 335,4 | 85261-19-4 |
| MEGA-10 (N-Decanoyl-N-methylglucamin) | D99008 | C16H33NO6 | 335,4 | 85261-19-4 |
| 1-O-(n-Octyl)-tetraethyleneglycol (C8E4) | D20038 | C16H34O5 | 306,44 | 19327-39-0 |
| 1-O-(n-Decyl)-hexaethyleneglycol (C10E6) | D20041 | C22H46O7 | 422,60 | 5168-89-8 |
| 1-O-(n-Decyl)-nonaethyleneglycol (C10E9) | D20033 | C28H58O10 | 554,75 | 26183-52-81 |
| 1-O-(n-Dodecyl)-tetraethyleneglycol (C12E4) | D20035 | C20H42O5 | 362,54 | 5274-68-0 |
| 1-O-(n-Dodecyl)-octaethyleneglycol (C12E8) | D20039 | C28H58O9 | 538,75 | 3055-98-9 |
| 1-O-(n-Dodecyl)-nonaethyleneglycol (C12E9) | D20032 | C30H62O10 | 582,81 | 3055-99-0 |
| 1-O-(n-Dodecyl)-decaethyleneglycol (C12E10) | D20031 | C32H66O11 | 626,86 | 6540-99-4 |
| 1-O-(n-Tridecyl)-octaethyleneglycol (C13E8) | D20030 | C29H60O9 | 552,78 | 9043-30-5 |
| N,N-Dimethyl-n-dodecylamine-N-oxide (LDAO) | D71111 | C14H31NO | 229,4 | 1643-20-5 |
| Sucrose monolaurate (SUMOL) | S98001 | C24H44NO12 | 524,6 | 25339-99-5 |
| Monoolein (1-O-Oleoyl-rac-glycerol) | D20036 | C21H40O4 | 356,5 | 111-03-5 |
| 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propane sulfonate | D99009 | C32H58N2O7S | 614,89 | 75621-03-3 |
| 3-[(3-Cholamidopropyl)-dimethylammonio]-2-hydroxy-1-propane sulfonate | D99010 | C32H58N2O8S | 630,87 | 82473-24-3 |
| n-Nonyl-phosphocholine (C9-PC) Purity > 99% | S10197 | C14H32NO4P | 309,38 | 253678-64-7 |
| n-Decyl-phosphocholine (C10-PC) Purity > 99% | S10195 | C15H34NO4P | 323,41 | 70504-28-8 |
| n-Undecyl-phosphocholine (C11-PC) Purity > 99% | S10196 | C16H36NO4P | 337,4 | 253678-65-8 |
| n-Dodecyl-phosphocholine (C12-PC) Purity > 99% | S10190 | C17H38NO4P | 351,46 | 29557-51-5 |
| n-Tridecyl-phosphocholine (C13-PC) Purity > 99% | S10198 | C18H40NO4P | 365,49 | 85775-42-4 |
| n-Tetradecyl-phosphocholine (C14-PC) Purity > 99% | S10194 | C19H42NO4P | 379,51 | 77733-28-9 |
| n-Pentadecyl-phosphocholine (C15-PC) Purity > 99% | S10199 | C20H44NO4P | 393,54 | 146801-07-2 |
| n-Hexadecyl-phosphocholine (C16-PC) Purity > 99% | S01241 | C21H46NO4P | 407,57 | 58066-85-6 |
| α-D-Galactopyranose-phosphate di-potassium salt dihydrate | P0001 | C6H11K2O9P. 2H2O | 372,36 | 19046-60-7 |
| α-D-Glucopyranose-phosphate di-potassium salt dihydrate | P0002 | C6H11K2O9P. 2H2O | 372,36 | 5996-14-5 |
| α-D-Mannopyranose-phosphate di-potassium salt dihydrate | P0003 | C6H11K2O9P. 2H2O | 372,36 | 71888-67-0 |
| N-Acetyl-D-galactosamine (2-Acetamido-2-deoxy-D-galactose, GalNAc) | S96001 | C8H15NO6 | 221,21 | 1811-31-0 |
| N-Acetyl-D-glucosamine (2-Acetamido-2-deoxy-D-glucose, GlcNAc) | S93002 | C8H15NO6 | 221,21 | 7512-17-6 |
| 2-Acetamido-2-deoxy-β-D-glucopyranosylamin | S98003 | C8H16N2O5 | 220,21 | 18615-50-4 |
| N-Acetyl-D-mannosamine x H2O (2-Acetamido-2-deoxy-D-mannose monohydrate, D-ManAc x H2O) | S94004 | C8H17NO7 | 239,23 | 7772-94-3 |
| 1,3,4,6-tetra-O-acetyl-β-D-GlcNAc (2-Acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose) | S94005 | C16H23NO10 | 389.36 | 7772-79-4 |
| 3,4,6-tri-O-acetyl-β-D-GlcNAc azide (2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl azide) | S96006 | C14H20N4O8 | 372,34 | 6205-69-2 |
| 3,4,6-tri-O-acetyl-α-D-GlcNAc chlorid (2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chlorid) | S97007 | C14H20CINO8 | 366,80 | 3068-34-6 |
| 1,3,4,6-tetra-O-acetyl-α-D-glucosamine x HCl (2-Amino-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose HCl) | S00116 | C14H22CINO9 | 383,79 | N/A |
| Allyl 2-acetamido-2-deoxy-α-D-glucopyranoside | S96008 | C11H19NO6 | 261,28 | 54400-75-8 |
| Allyl 2-acetamido-2-deoxy-β-D-glucopyranoside | S96009 | C11H19NO6 | 261,28 | 54400-77-0 |
| Allyl α-D-galactopyranoside | S96010 | C9H16O6 | 220,22 | 48149-72-0 |
| Allyl α-D-glucopyranoside | S98011 | C9H16O6 | 220,22 | 7464-56-4 |
| Allyl β-D-glucopyranoside | S98012 | C9H16O6 | 220,22 | 34384-797 |
| Allyl α-D-mannopyranoside | S11118 | C9H16O6 | 220,22 | 41308-76-3 |
| Allyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside | S98013 | C30H34O6 | 490,60 | N/A |
| 1-Amino-1-deoxy-β-D-galactose (β-D-Galactopyranosylamine) | S99102 | C6H13NO5 | 179,17 | 50444-86-5 |
| 1,6-Anhydro-β-D-galactopyranose | S93014 | C6H10O5 | 162,14 | 644-76-8 |
| 1,6:3,4-Dianhydro-2-O-tosyl-β-D-galactopyranose | S97016 | C13H14O6s | 234,25 | 6167-32-4 |
| D-Arabinose | S93017 | C5H10O5 | 150,13 | 28697-53-2 |
| Arbutin (4-Hydroxyphenyl b-D-glucopyranoside, synthetic) | S96018 | C12H16O7 | 272,25 | 497-76-7 |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-galactopyranose | S96021 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α,β-D-galactopyranose | S97022 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose | S96024 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,2‘,3,3‘,4‘,6,6‘-hepta-O-acetyl-α,β-lactose 2-Azido-2-deoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-1,3,6-tri-O-acetyl-α,β-D-glucopyranose | S96025 | C26H35N3O17 | 661,58 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-mannopyranose | S97026 | C14H19N3O9 | 373,32 | N/A |
| Benzyl 4,6-O-benzylidene-α-D-GlcNAc | S97027 | C22H25NO6 | 399,45 | 13343-63-0 |
| Benzyl α-D-GlcNAc (Benzyl 2-acetamido-2-deoxy-α-D-glucopyranoside) | S97028 | C15H21NO6 | 311,34 | 13343-62-9 |
| Benzyl α-D-mannopyranoside | S97029 | C13H18O6 | 270,28 | 155548-45-5 |
| Cellobiose | S96030 | C12H22O11 | 342,30 | 528-50-7 |
| 6-Deoxy-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose | S96032 | C12H20O5 | 244,29 | 4026-27-1 |
| 3,4-Di-O-acetyl-L-rhamnal (3,4-Di-O-acetyl-6-deoxy-L-glucal) | S94035 | C10H14O5 | 214.22 | 34819-86-8 |
| 1,4:3,6-Dianhydro-D-mannitol | S97037 | C6H10O4 | 146,15 | 641-74-7 |
| 1,2,3,4-Di-O-isopropylidene-α-D-galactopyranose | S95038 | C12H20O6 | 260.29 | 4064-06-6 |
| 1,2:5,6-Di-O-isopropylidene-α-D-glucofuranose | S00112 | C12H20O6 | 260,29 | 582-52-5 |
| 1,2:5,6-Di-O-isopropylidene-D-mannitol | S95039 | C12H22O6 | 262,31 | 1707-77-3 |
| 2,3:5,6-Di-O-isopropylidene-α-D-mannofuranose | S93040 | C12H20O6 | 260.29 | 14131-84-1 |
| 1,2:3,5-Di-O-isopropylidene-α-D-xylofuranose | S00110 | C11H18O5 | 230,26 | 20881-04-3 |
| D-Fucose (6-Deoxy-D-galactose) | S96042 | C6H12O6 | 164,16 [3615-37-0] | 3615-37-0 |
| L-Fucose (6-Deoxy-L-galactose) | S96043 | C6H12O6 | 164,16 | 2438-80-4 |
| D-Galactosamine x HCl | S95044 | C6H13NO5 x HCl | 215.64 | 1172-03-8 |
| D-Glucosamine x HCl | S93045 | C6H13NO5 x HCl | 215.64 | 66-84-2 |
| L-Glucose | S94046 | C6H12O6 | 180.16 | 921-60-8 |
| 2,3,3’,4,6,6’-Hexa-O-acetyl-lactal | S97036 | N/A | N/A | |
| 1,2-O-Isopropylidene-α-D-glucofuranose | S00113 | C9H16O6 | 220,22 | 18549-40-1 |
| Isopropyl-β-D-thiogalactoside IPTG (lactose based) | S02122-L | C9H18O5S | 238,31 | 367-93-1 |
| Isopropyl-β-D-thiogalactoside IPTG (on plant based) | S02122-P | C9H18O5S | 238,31 | 367-93-1 |
| 3,4-O-Isopropylidene-D-mannitol | S94048 | C9H18O6 | 222,22 | 369-84-4 |
| 1,2-O-Isopropylidene-α-D-xylofuranose | S00111 | C8H14O5 | 190,20 | 20031-21-4 |
| D-Lyxose | S96051 | C5H10O5 | 150,13 | 1114-34-7 |
| L-Lyxose | S96052 | C5H10O5 | 150,13 | 1949-78-6 |
| Maltose monohydrate | S98053 | C12H22O11H2O | 360,32 | 6363-53-7 |
| β-Maltose octaacetate | S98054 | C28H38O19 | 678,63 | 22352-19-8 |
| D-Mannose | S93057 | C6H12O6 | 180.16 | 3458-28-4 |
| L-Mannose | S94058 | C6H12O6 | 180.16 | 10030-80-5 |
| Methyl 4,6-O-benzylidene-β-D-galactopyranoside | S96060 | C14H18O6 | 282,30 | 6988-39-2 |
| Methyl 4,6-O-benzylidene-α-D-glucopyranoside | S97061 | C14H18O6 | 282,30 | 3162-96-7 |
| Methyl 4,6-O-benzylidene-β-D-glucopyranoside | S98062 | C14H18O6 | 282,30 | 6988-39-2 |
| Methyl 6-deoxy-α-L-mannopyranoside (Methyl a-L-rhamnopyranoside) | S96063 | C7H14O5 | 178,19 | 15814-59-2 |
| Methyl α-D-fucopyranoside | S96064 | C7H14O5 | 178,19 | 1128-40-1 |
| Methyl α-L-fucopyranoside | S96065 | C7H14O5 | 178,19 | 14687-15-1 |
| Methyl β-D-galactopyranoside | S96066 | C7H14O6 | 194,18 | 1824-94-8 |
| Methyl β-D-glucopyranoside hemihydrate | S96067 | C7H14O6 | 194,18 | 7000-27-3 |
| Methyl β-D-ribopyranoside | S97068 | C6H12O5 | 164,16 | 17289-61-1 |
| Methyl 2,3,5-tri-O-benzoyl-α-D-arabinofuranoside | S98069 | C27H24O8 | 476,49 | N/A |
| 1,2,3,4,6-Penta-O-acetyl-β-D-galactopyranose | S95072 | C16H22O11 | 390,35 | 4163-60-4 |
| 1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose | S99070 | C16H22O11 | 390,35 | 4163-65-9 |
| D-Raffinose pentahydrate | S96074 | C18H32O16 5H2O | 594,53 | 17629-30-0 |
| L-Rhamnose monohydrate | S94075 | C6H14O6 | 182.17 | 10030-85-0 |
| D-Ribose | S93076 | C5H10O5 | 150.13 | 50-69-1 |
| L-Ribose | S93077 | C5H10O5 | 150.13 | 24259-59-4 |
| D-Tagatose | S93079 | C6H12O6 | 180.16 | 87-81-0 |
| α-D-Talose | S93080 | C6H12O6 | 180.16 | 2595-98-4 |
| 2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl azide | S96081 | C14H19N3O9 | 373,32 | 13992-26-2 |
| 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide | S96082 | C14H19BrO9 | 411.21 | 3068-32-4 |
| 2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl azide | S96083 | C14H19N3O9 | 373,32 | 13992-25-1 |
| 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide | S94084 | C14H19BrO9 | 411.21 | 572-09-8 |
| 1,3,4,6-Tetra-O-acetyl-β-D-mannopyranose | S97086 | C14H20O10 | 348,31 | 18968-05-3 |
| 2,3,4,6-Tetra-O-acetyl-α-D-mannopyranose | S97087 | C14H20O10 | 348,31 | N/A |
| 1,2,3,5-Tetra-O-acetyl-β-D-ribofuranose | S94088 | C13H18O9 | 318.28 | 13035-61-5 |
| 2,3,4,6-Tetra-O-acetyl-1-thio-β-D-galactopyranose | S94089 | C14H20O9S | 364.37 | N/A |
| 2,3,4,6-Tetra-O-acetyl-1-thio-β-D-glucopyranose | S94090 | C14H20O9S | 364.37 | 19879-84-6 |
| 2,3,4,6-Tetra-O-benzyl-α-D-galactopyranose | S96091 | C34H3606 | 540.66 | 5308-25-7 |
| 2,3,4,6-Tetra-O-benzyl-α-D-glucopyranose | S93092 | C34H3606 | 540.66 | 4132-28-9 |
| 2,3,4,6-Tetra-O-benzyl-α-D-mannopyranose | S96093 | C34H3606 | 540.66 | 61330-61-8 |
| 1-Thio-β-D-galactose sodium salt | S96094 | C6H11NaO5S | 218,21 | 42891-22-5 |
| 1-Thio-β-D-glucose sodium salt dihydrate | S94095 | C6H11NaO5S x 2 H2O | 254.24 | 10593-29-0 |
| 3,4,6-Tri-O-acetyl-D-galactal | S94097 | C12H16O7 | 272.26 | 4098-06-0 |
| D-Turanose (α-D-Glcp(1-3)-D-fructose) | S93100 | C12H22O11 | 342.30 | 547-25-1 |
| D-Xylose | S93101 | C5H10O5 | 150.13 | 58-86-6 |
| 1,6-Anhydro-β-D-glucopyranose (Levoglucosan) | S93015 | C6H10O5 | 162,14 | 498-07-7 |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose | S96023 | C14H19N3O9 | 373,32 | N/A |
我们承诺:
(1)专业的服务:为您提供包括购买咨询、技术支持及实验方案制定在内的全方位服务;
(2)迅捷的货期:利用国际化的物流平台,大大缩短产品从厂家到最终用户的时间;
(3)过硬的品质:确保正品、质量和售后,多年客户积累,口碑保证。
公司简介:
艾美捷科技有限公司经营范围涵盖分子生物学试剂、免疫学试剂、细胞生物学试剂、蛋白质研究试剂、微生物学试剂、化学及生化试剂、材料学试剂、天然提取物、仪器设备等9大门类,累计约10万余种产品,充分满足不同客户的个性化需求;公司代理国外50余种一线品牌试剂,以“高性价比、迅捷的物流速度、专业的技术支持”,让客户充分享受全球化带来的便利;公司还增加了基因编辑、蛋白表达、细胞鉴定等定制项目,大大提升了为客户服务能力。“不忘初心,方得始终”,艾美捷科技将继续秉持“专心、专业、为您”的宗旨,以客户为根本,以诚信为基础,持续地为各界客户提供更加优质的产品和服务。
Glycon Biochemicals GmbH; Glycon Biochem; Glycon; S20031; S97085; S10191; S10192; S10189; S03293; S05174; S02174; D-20054; D-20055; D-20056; D97011; D20034; D99014; D07033; D97001; D97001-C; D99011; D99011-C; D99006; D11023; D99007; D99019-C; D99020; D20018; D14001; D20020; D20015; D20015-C; D99003; D99003-C; D99012; D99012-C; D97002-C; D20016; D20016-C; D20028-C; D20040-C; D20029-C; D97002; S02122; D99013; D20014; D14038-C; D20021; D20022-C; D99013-C; D20014-C; D98004; D99005; D99008; D20038; D20041; D20033; D20035; D20039; D20032; D20031; D20030; D71111; S98001; D20036; D99009; D99010; S10197; S10195; S10196; S10190; S10198; S10194; S10199; S01241; P0001; P0002; P0003; S96001; S93002; S98003; S94004; S94005; S96006; S97007; S00116; S96008; S96009; S96010; S98011; S98012; S11118; S98013; S99102; S93014; S97016; S93017; S96018; S96021; S97022; S96024; S96025; S97026; S97027; S97028; S97029; S96030; S96032; S94035; S97037; S95038; S00112; S95039; S93040; S00110; S96042; S96043; S95044; S93045; S94046; S97036; S00113; S02122-L; S02122-P; S94048; S00111; S96051; S96052; S98053; S98054; S93057; S94058; S96060; S97061; S98062; S96063; S96064; S96065; S96066; S96067; S97068; S98069; S95072; S99070; S96074; S94075; S93076; S93077; S93079; S93080; S96081; S96082; S96083; S94084; S97086; S97087; S94088; S94089; S94090; S96091; S93092; S96093; S96094; S94095; S94097; S93100; S93101; S93015; S96023; 10030-80-5; 10030-85-0; 10593-29-0; 106402-05-5; 106402-05-5; 111-03-5; 1114-34-7; 1128-40-1; 115457-83-5; 116183-64-3; 1172-03-8; 13035-61-5; 13343-62-9; 13343-63-0; 13992-25-1; 13992-26-2; 14131-84-1; 146801-07-2; 14687-15-1; 148565-58-6; 155548-45-5; 15814-59-2; 1643-20-5; 1707-77-3; 17289-61-1; 17629-30-0; 1811-31-0; 1824-94-8; 18449-82-6; 18549-40-1; 18615-50-4; 18968-05-3; 19046-60-7; 19327-39-0; 1949-78-6; 19879-84-6; 20031-21-4; 20881-04-3; 22352-19-8; 24259-59-4; 2438-80-4; 25339-99-5; 253678-64-7; 253678-65-8; 253678-67-0; 253678-67-0; 2595-98-4; 26183-52-81; 28697-53-2; 29557-51-5; 29781-80-4; 29836-26-8; 29836-26-8; 3055-98-9; 3055-99-0; 3068-32-4; 3068-34-6; 3162-96-7; 34384-797; 3458-28-4; 34819-86-8; 3615-37-0; 367-93-1; 367-93-1; 367-93-1; 369-84-4; 4026-27-1; 4064-06-6; 4098-06-0; 41308-76-3; 4132-28-9; 4163-60-4; 4163-65-9; 48149-72-0; 497-76-7; 498-07-7; 50444-86-5; 50-69-1; 5168-89-8; 5274-68-0; 528-50-7; 5308-25-7; 54400-75-8; 54400-77-0; 547-25-1; 572-09-8; 58066-85-6; 582-52-5; 58846-77-8; 58-86-6; 59080-45-4; 59122-55-3; 5996-14-5; 61330-61-8; 6167-32-4; 6205-69-2; 6363-53-7; 641-74-7; 644-76-8; 6540-99-4; 66-84-2; 69227-93-6; 69227-93-6; 6988-39-2; 6988-39-2; 69984-73-2; 69984-73-2; 7000-27-3; 70005-86-6; 70504-28-8; 71888-67-0; 7464-56-4; 7512-17-6; 75621-03-3; 7772-79-4; 7772-94-3; 77733-28-9; 78617-12-6; 82473-24-3; 82494-08-4; 82494-09-5; 82494-09-5; 85261-19-4; 85261-19-4; 85316-98-9; 85618-20-8; 85618-20-8; 85618-21-9; 85618-21-9; 85775-42-4; 870287-95-9; 87-81-0; 9043-30-5; 921-60-8; 93911-12-7; 93911-12-7; 98064-96-1; 98854-15-0; 98854-16-1

Polymer Source公司成立于1994年,致力于为世界范围的客户提供高品质的Deuterated Polymers 氘代聚合物和Protonated Polymers质子化聚合物。
Since its inception in 1994, Polymer Source Inc. takes great pride in supplying a high quality of architecturally controlled specialty polymers in the world of research and development. Our research team comprises of dynamic, competent and innovative scientists who excel in supplying top class service to various research institutions. Within a span of six years our team has accomplished the production of over 3000 block copolymers that have gained worldwide recognition.





Polymer Source公司的主要产品包括:
Deuterated Homopolymers 氘代均聚物
Deuterated Block Copolymers 氘代嵌段共聚物
Deuterated Functionlized Polymers 氘代功能聚合物
Deuterated Random and Alternating Copolymers 氘代无规和交替共聚物
Deuterated Monomers 氘代单体
Deuterated Oligomers (Dimer & Trimer etc.) 氘代齐聚物(二聚物和三聚物等)
C13 Labeled Polymers C13标示聚合物
Monomers-High Purity 高纯单体
Hydrophobic Polymers 憎水聚合物
Hydrophilic Polymers 亲水聚合物
Diblock Copolymers 双嵌段共聚物
Amphiphilic Block Copolymers 两性嵌段共聚物
A-B-A Triblock Copolymers A-B-A三嵌段共聚物
A-B-C Triblock Copolymers A-B-C三嵌段共聚物
Random and Alternating Copolymers 无规和交替共聚物
Functionalized Polymers 功能聚合物
Star-like Polymers 星形聚合物
Comb-like Polymers 梳子形聚合物
Labeled Polymers 标示聚合物
Ionomers 离子聚合物
Oligomers (Dimer & Trimer etc.) 齐聚物(二聚物和三聚物等)
Conducting and Luminescence Polymers 导电和荧光聚合物
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Innovative Research of America(IRA) 是一家致力研发于药物定量定时缓释系统的专业化公司,又称Matrix-Driven Delivery (MDD) 给药系统。该给药系统由一个可生物吸收的基质组成,含有定量可控的活性给药成分,可以以设定的剂量在一定时间范围内进行给药。
Since it is not easy to administer drugs and hormones orally to research animals, several delivery methods have been devised as alternatives. However, most scientists continue to labor with unreliable injectables to conduct their research.
Matrix-Driven Delivery (MDD) Pellet(MDD片剂)的优势
Saves time
Ready-to-implant
Insures controlled product release over time
Avoids "peak and valley" effects
Guarantees consistent product preparation
Extends product life against spontaneous breakdown
Extends product life against host-related breakdown
Minimizes experimental variables
Insures safety of the experimenter
Reduces neurophysiological trauma to animal/no excessive handling
Generates more meaningful and reproducible results
Superior to conventional delivery methods
Enhances experimental efficiency
Frees valuable time for creative research
Saves money
Innovative Research of America的主要产品包括:
ANTIBIOTICS
ANTI-INFLAMMATORY AGENTS
ANTI-NEOPLASTICS
CATECHOLAMINES & RELATED PRODUCTS
CORTICOIDS & DIURETICS
ESTROGENS & ANTI-ESTROGENS
FATTY ACIDS
MISCELLANEOUS PRODUCTS
NUCLEOTIDE RELATED PRODUCTS
PLACEBO
PROGESTINS
PROSTAGLANDINS
THYROIDS
VITAMINS
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://synaptic.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Innovative Research of America"> Innovative Research of America
艾美捷科技代理Magtivio品牌磁珠产品
荷兰Magtivio BV是一家磁性微/纳米颗粒生产商,为生命科学和生物分析领域提供磁珠及完整试剂盒产品。Magtivio BV设计开发了两种类型的二氧化硅包覆氧化铁磁珠,其中包括:超顺磁
性磁珠,它们采用复合多孔结构设计,易于再悬浮,并表现出较低的沉降率;以及铁磁性磁珠,这些磁珠粒型由相对致密的核壳结构制成,具有强磁性,更适合大体积和粘性样品。末端官能
化的基团可以连接到两种磁珠类型的二氧化硅涂层。Magtivio BV的产品包括:
(1)核酸纯化:MagSi-(D)NA试剂盒和磁珠作为固体支持相,从病原体、植物和动物组织、体液和细胞中分离核酸。
(2)DNA纯化:MagSi试剂盒,用于测序应用中的PCR 纯化、DNA大小选择。
(3)免疫测定:MagSi链霉亲和素珠用作固相,易于结合生物素化的生物分子。
(4)蛋白质分析:具有改性表面的MagSi微珠,用于蛋白质的纯化和分离,用于质谱、蛋白质组学分析和生物标志物研究。
(5)研究工具:表面活化的MagSi微珠,用于固定蛋白质、肽、核酸或其他感兴趣的分子;MagSi 平台具有广泛的功能化可能性。
(6)LCMS样品制备:在LC-MS/MS分析之前,基于MagSiMUS磁珠的生物样品制备,用于蛋白质耗竭和从生物样品中去除其他干扰化合物。
(7)SafeQ:用于样本采集、储存和释放的解决方案,例如唾液采集试剂盒
(8)磁选机:用于从液体样品中磁分离MagSi和MagSiMUS磁珠。
(9)rQ " data-original="http://synaptic.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Magtivio品牌磁珠产品">
艾美捷科技代理Magtivio品牌磁珠产品

OXOID的主要产品包括:
Agars
Air Sampler
Antimicrobial Susceptibility Discs In Cartridges
Antimicrobial Susceptibility Testing
Atmosphere Generation System
Biochemical Reagents
Blood Culture
Culti-Loops
Culture Media Supplements
Dehydrated Culture Media
Diagnostic Discs
Diagnostic Reagents
Dip Slides
EIA Test Components Veterinary
EIA Test Veterinary
Food Allergen tests
IDEIA Accessories
IDEIA EIA Test
IMAGEN Accessories
IMAGEN Immunofluorescence Test
Laboratory Preparations/Biological Extracts
Microbact Biochemical Identification Kits
Molecular Microbiology
Oxoid Biochemical Identification System (O.B.I.S.)
Prepared Media
Prepared Media - Bottled Culture Media
Prepared Media - Ready Prepared Plates
Publications
Quanti-Cult
Rapid Food Tests
Remel - Agglutinating Sera
Remel - Collection and Transport
Remel - Diagnostic Kits
Remel - Diagnostic Tests
Remel - Laboratory Supplies
Remel - Quality Control
Remel - Reagents and Stains
Remel - Stained Suspensions
Test Tube Caps
Toxin Detection Kits
Transport Swabs
Veggietones
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:15172431432
邮箱:sales@amyjet.com
0.2997